A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma.
Authors
Clamp, Andrew RBlackhall, Fiona H
Vasey, P
Soukop, M
Coleman, R
Halbert, G
Robson, L
Jayson, Gordon C
Affiliation
Cancer Research UK Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Withington, Manchester, M20 4BX, UK. aclamp@picr.man.ac.ukIssue Date
2003-10-06
Metadata
Show full item recordAbstract
Bryostatin-1 is a macrocyclic lactone whose main mechanism of action is protein kinase C modulation. We investigated its activity as a weekly 24-h infusion in recurrent ovarian carcinoma. In all, 17 patients were recruited and 11 had chemotherapy-resistant disease as defined by disease progression within 4 months of last cytotoxic therapy. All were evaluable for toxicity and 14 for response. There were no disease responses and the main toxicity was myalgia.Citation
A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma. 2003, 89 (7):1152-4 Br. J. CancerJournal
British Journal of CancerDOI
10.1038/sj.bjc.6601285PubMed ID
14520436Type
ArticleLanguage
enISSN
0007-0920ae974a485f413a2113503eed53cd6c53
10.1038/sj.bjc.6601285
Scopus Count
Collections
Related articles
- A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma.
- Authors: Blackhall FH, Ranson M, Radford JA, Hancock BW, Soukop M, McGown AT, Robbins A, Halbert G, Jayson GC, Cancer Research Campaign Phase I/II Committee
- Issue date: 2001 Feb
- Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study.
- Authors: Nezhat F, Wadler S, Muggia F, Mandeli J, Goldberg G, Rahaman J, Runowicz C, Murgo AJ, Gardner GJ
- Issue date: 2004 Apr
- Phase Ib trial of bryostatin 1 in patients with refractory malignancies.
- Authors: Grant S, Roberts J, Poplin E, Tombes MB, Kyle B, Welch D, Carr M, Bear HD
- Issue date: 1998 Mar
- Weekly bryostatin-1 in metastatic renal cell carcinoma: a phase II study.
- Authors: Haas NB, Smith M, Lewis N, Littman L, Yeslow G, Joshi ID, Murgo A, Bradley J, Gordon R, Wang H, Rogatko A, Hudes GR
- Issue date: 2003 Jan
- A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer.
- Authors: Zonder JA, Shields AF, Zalupski M, Chaplen R, Heilbrun LK, Arlauskas P, Philip PA
- Issue date: 2001 Jan